These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30746927)

  • 1. Overlapping irritable bowel syndrome and inflammatory bowel disease.
    Gajula P; Quigley EM
    Minerva Gastroenterol Dietol; 2019 Jun; 65(2):107-115. PubMed ID: 30746927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The overlap between IBS and IBD: what is it and what does it mean?
    Stanisic V; Quigley EM
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):139-45. PubMed ID: 24417262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity.
    Berrill JW; Green JT; Hood K; Campbell AK
    Aliment Pharmacol Ther; 2013 Jul; 38(1):44-51. PubMed ID: 23668698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life.
    Ozer M; Bengi G; Colak R; Cengiz O; Akpinar H
    Medicine (Baltimore); 2020 May; 99(19):e20067. PubMed ID: 32384473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?
    Nemakayala DR; Cash BD
    Curr Opin Gastroenterol; 2019 Jan; 35(1):58-62. PubMed ID: 30407259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.
    Halpin SJ; Ford AC
    Am J Gastroenterol; 2012 Oct; 107(10):1474-82. PubMed ID: 22929759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
    Menees SB; Powell C; Kurlander J; Goel A; Chey WD
    Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is irritable bowel syndrome a low-grade inflammatory bowel disease?
    Bercik P; Verdu EF; Collins SM
    Gastroenterol Clin North Am; 2005 Jun; 34(2):235-45, vi-vii. PubMed ID: 15862932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease.
    Fairbrass KM; Selinger CP; Gracie DJ; Ford AC
    Neurogastroenterol Motil; 2022 May; 34(5):e14256. PubMed ID: 34472157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?
    Burgmann T; Clara I; Graff L; Walker J; Lix L; Rawsthorne P; McPhail C; Rogala L; Miller N; Bernstein CN
    Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Debatable aspects of pathogenesis and diagnostics of irritable bowel syndrome (IBS) and inflammatory bowel diseases with IBS-like diseases].
    Pogromov AP; Tashchyan OV; Mnatsakanyan MG; Dyukova GM
    Klin Med (Mosk); 2010; 94(10):795-800. PubMed ID: 30299054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Irritable bowel syndrome and inflammatory bowel disease: Is there a connection?].
    Mearin F; Perelló A; Balboa A
    Gastroenterol Hepatol; 2009 May; 32(5):364-72. PubMed ID: 19442413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
    Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
    Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
    Aziz I; Simrén M
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):139-148. PubMed ID: 33189181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Fairbrass KM; Hamlin PJ; Gracie DJ; Ford AC
    Aliment Pharmacol Ther; 2022 Oct; 56(8):1264-1273. PubMed ID: 35995729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Fairbrass KM; Costantino SJ; Gracie DJ; Ford AC
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1053-1062. PubMed ID: 33010814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain.
    Jelsness-Jørgensen LP; Bernklev T; Moum B
    Gastroenterol Nurs; 2014; 37(4):280-7. PubMed ID: 25078042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.